The popularity of Sildenafil initially drove a boom for the drug industry, but recent developments present a complicated picture for shareholders. Lower-cost competitors are eating into revenue, and persistent patent https://mathenqxp377483.blogars.com/39675242/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-investment